Form 4: CEO Exercises, Sells UTHR Stock Under 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock totaling 8,000 shares over two days in November 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving the exercise of stock options and subsequent sale of common stock.
• On November 4, 2025, 4,000 stock options were exercised at an exercise price of $120.26 per share.
• On the same day, 4,000 shares of common stock were sold at weighted average prices ranging from $432.75 to $435.0658.
• On November 5, 2025, another 4,000 stock options were exercised at $120.26 per share.
• Also on November 5, 2025, 4,000 shares of common stock were sold at weighted average prices ranging from $432.53 to $442.262.
• All transactions were conducted under a pre-arranged 10b5-1 trading plan established on May 2, 2025.
• The plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, direct beneficial ownership of common stock remained at 130 shares.
• The number of beneficially owned stock options decreased by 8,000, from 126,000 to 118,000.
• Indirect beneficial ownership includes 166 shares by spouse and 644,193 shares across various family trusts.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions under a pre-arranged plan. While the sale of shares by a CEO could be seen as slightly negative, the planned nature and the significant profit from option exercise make it a neutral to slightly positive event from a compliance and personal finance perspective for the insider. It does not reflect negatively on the company's operational performance or future prospects directly.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to insider stock sales, which can mitigate concerns about opportunistic selling.
• The exercise price of the options ($120.26) is significantly lower than the sale prices (ranging from $432.53 to $442.262), indicating a substantial profit for the reporting person on these specific transactions.

Negatives

• The CEO sold a significant number of shares (8,000 shares) over two days, which could be interpreted as a reduction in direct exposure to the company's stock, although it is part of a pre-arranged plan.
• The total number of stock options beneficially owned by the CEO decreased by 8,000, reducing potential future upside from these specific options.

Future Outlook

The 10b5-1 trading plan is scheduled to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025, indicating potential for further similar transactions in the near future.

Industry Context

This Form 4 filing reports routine insider transactions for a biotechnology company. Such transactions are common for executives managing their personal portfolios, especially when exercising expiring stock options. The prices at which the shares were sold reflect the market valuation of United Therapeutics Corp (UTHR) at the time of the transactions, which can be influenced by broader trends in the pharmaceutical and biotech sectors, including drug development progress, regulatory approvals, and market competition. The use of a 10b5-1 plan is a standard practice for insiders to sell shares without being accused of trading on material non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan by a CEO is a common and accepted practice for managing personal stock holdings and exercising options in a compliant manner within the U.S. financial industry.
• The significant difference between the option exercise price ($120.26) and the sale prices (over $430) is typical for long-held, in-the-money executive stock options in successful companies, reflecting substantial stock price appreciation over time.
• The reported indirect ownership through various trusts is also a standard wealth management strategy for high-net-worth individuals, including corporate executives.

Stakeholder Impact

• Shareholders: May view the CEO's sale of shares as a slight negative, but the pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. The transactions demonstrate the value of executive compensation tied to stock performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The 10b5-1 trading plan may involve further exercises and sales of the remaining tranche of 294,000 stock options until December 31, 2025, or until the options expiring March 15, 2026, are exhausted.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions by the CEO under a pre-arranged 10b5-1 plan. It reflects the exercise of stock options and subsequent sale of shares, which is a common practice for executive compensation and personal financial management. The transactions do not provide new information regarding the company's operational performance, financial health, or strategic direction. Therefore, based solely on this filing, there is no basis to change an existing investment thesis, warranting a 'hold' recommendation.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO Stock Sale, Biotechnology, Pharmaceuticals